1,721,286 research outputs found
Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study
No full textObjectiveTo investigate the clinical use patterns, clinical effect and safety of cyclosporine A (CSA) in juvenile idiopathic arthritis (JIA) in the setting of routine clinical care.MethodsAn open-ended, phase IV post marketing surveillance study was conducted among members of the Pediatric Rheumatology Collaborative Study Group (PRCSG) and of the Paediatric Rheumatology International Trials Organisation (PRINTO) to identify patients with polyarticular course JIA who had received CSA during the course of their disease.ResultsA total of 329 patients, half of whom had systemic JIA, were collected in 21 countries. Data were collected during 1240 routine clinic visits. CSA was started at a mean of 5.8 years after disease onset and was given at a mean dose of 3.4 mg/kg/day. The drug was administered in combination with MTX in 61% and along with prednisone in 65% of the patients who were still receiving CSA. Among patients who were still receiving CSA therapy at the last reported visit, remission was documented in 9% of the patients, whereas in 61% of the patients the disease activity was rated as moderate or severe. The most frequent reason for discontinuation of CSA was insufficient therapeutic effect (61% of the patients); only 10% of the patients stopped CSA because of remission. In 17% of the patients, side effects of therapy was given as the primary reason for discontinuation.ConclusionThis survey suggests that CSA may have a less favourable efficacy profile than MTX and etanercept, whereas the frequency of side effects may be similar. The exact place of CSA in the treatment of JIA can only be established via controlled clinical trial.Univ Genoa, PRINTO, IRCCS G Gaslini, I-16147 Genoa, ItalyIst Gaetano Pini, Div Reumatol, Milan, ItalyRheumakinder Klin Germisch Partenkirchen, Rummelsberger Anstalten Inneren Miss EV, Garmisch Partenkirchen, GermanyPoliclin San Matteo, IRCCS, I-27100 Pavia, ItalyUniv Thessaloniki, Dept Pediat, Ippokration Gen Hosp, GR-54006 Thessaloniki, GreeceRigshosp, Juliane Marie Ctr, Pediat Klin 2, DK-4064 Copenhagen, DenmarkUniv Utah, Dept Pediat, Salt Lake City, UT USAChildrens Hosp, Div Pediat Rheumatol, Columbus, OH 43205 USAUniv Athens, PA Kyriakou Childrens Hosp, Dept Paediat 2, Athens, GreeceNatl Inst Rheumatism & Physiotherapy, Gen & Pediat Rheumatol Dpt 3, Budapest, HungaryUniv Trieste, Trieste, ItalyFD Roosvelt Hosp, Paediat Clin, Banska Bystrica 97517, SlovakiaWilhelmina Childrens Hosp, Dept Pediat Immunol & Rheumatol, Utrecht, NetherlandsUniv Fed Rio de Janeiro, Inst Puericultura & Pediat Martagao Gesteira, Rio De Janeiro, BrazilHosp Pediat Prof Dr Juan P Garrahan, Serv Immunol, Buenos Aires, DF, ArgentinaUniv Fed Sao Paulo, Sao Paulo, BrazilIRCCS, Ist Giannina Gaslini, Clin Pediat 1, Genoa, ItalyChildrens Hosp, Med Ctr, Div Rheumatol, Cincinnati, OH 45229 USAHosp Univ La Paz, Unidad Reumatol Pediat, Madrid, SpainUniv Fed Sao Paulo, Sao Paulo, BrazilWeb of Scienc
Safety and effectiveness of abatacept in juvenile idiopathic arthritis : results from the PRINTO/PRCSG registry
No full textPublisher Copyright: © 2024 The Author(s).OBJECTIVE: The aim of this study was to report the interim 5-year safety and effectiveness of abatacept in patients with JIA in the PRINTO/PRCSG registry. METHODS: The Abatacept JIA Registry (NCT01357668) is an ongoing observational study of children with JIA receiving abatacept; enrolment started in January 2013. Clinical sites enrolled patients with JIA starting or currently receiving abatacept. Eligible patients were assessed for safety (primary end point) and effectiveness over 10 years. Effectiveness was measured by clinical 10-joint Juvenile Arthritis Disease Activity Score (cJADAS10) in patients with JIA over 5 years. As-observed analysis is presented according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. RESULTS: As of 31 March 2020, 587 patients were enrolled; 569 are included in this analysis (including 134 new users) with 1214.6 patient-years of safety data available. Over 5 years, the incidence rate (IR) per 100 patient-years of follow-up of serious adverse events was 5.52 (95% CI: 4.27, 7.01) and of events of special interest was 3.62 (95% CI: 2.63, 4.86), with 18 serious infections [IR 1.48 (95% CI: 0.88, 2.34)]. As early as month 3, 55.9% of patients achieved cJADAS10 low disease activity and inactive disease (20.3%, 72/354 and 35.6%, 126/354, respectively), sustained over 5 years. Disease activity measures improvement over 5 years across JIA categories. CONCLUSION: Abatacept was well tolerated in patients with JIA, with no new safety signals identified and with well-controlled disease activity, including some patients achieving inactive disease or remission. TRIAL REGISTRATION: Clinicaltrials.gov, NCT01357668.Peer reviewe
Safety and effectiveness of abatacept in juvenile idiopathic arthritis: Results from the PRINTO/PRCSG registry
No full textObjective: The aim of this study was to report the interim 5-year safety and effectiveness of abatacept in patients with JIA in the PRINTO/PRCSG registry. Methods: The Abatacept JIA Registry (NCT01357668) is an ongoing observational study of children with JIA receiving abatacept; enrolment started in January 2013. Clinical sites enrolled patients with JIA starting or currently receiving abatacept. Eligible patients were assessed for safety (primary end point) and effectiveness over 10 years. Effectiveness was measured by clinical 10-joint Juvenile Arthritis Disease Activity Score (cJADAS10) in patients with JIA over 5 years. As-observed analysis is presented according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. Results: As of 31 March 2020, 587 patients were enrolled; 569 are included in this analysis (including 134 new users) with 1214.6 patient-years of safety data available. Over 5 years, the incidence rate (IR) per 100 patient-years of follow-up of serious adverse events was 5.52 (95% CI: 4.27, 7.01) and of events of special interest was 3.62 (95% CI: 2.63, 4.86), with 18 serious infections [IR 1.48 (95% CI: 0.88, 2.34)]. As early as month 3, 55.9% of patients achieved cJADAS10 low disease activity and inactive disease (20.3%, 72/354 and 35.6%, 126/354, respectively), sustained over 5 years. Disease activity measures improvement over 5 years across JIA categories. Conclusion: Abatacept was well tolerated in patients with JIA, with no new safety signals identified and with well-controlled disease activity, including some patients achieving inactive disease or remission
PRINTO scholarships: the Italian experience
No full textAbstract The increasing availability of the internet allows physicians to access actualized medical information quickly and easily, but it is not comparable with the possibility of working in a well known international medical centre. International collaboration (scholarships, courses and research), such as the PRINTO alpha project, allows professionals not only to increase and share scientific knowledge and experiences but also to integrate into a working team in a foreign country which leads to an understanding among cultures. PRINTO has set up a scientific and technical collaborative research network in Paediatric Rheumatology for Latin American physicians.</p
Performance of Tel-Hashomer, Livneh, pediatric and new Eurofever/PRINTO classification criteria for familial Mediterranean fever in a referral center
No full textUntil now, the diagnosis of familial Mediterranean fever (FMF) was based on validated subsets of clinical criteria, but recently new Eurofever/PRINTO classification criteria concerning genetic analyses were proposed. The study aimed to compare the performances of three validated diagnostic criteria (Tel-Hashomer, Livneh, pediatric criteria) and new Eurofever/PRINTO classification criteria. The medical charts of study and control groups were reviewed retrospectively. Patients were evaluated for three diagnostic criteria and new Eurofever/PRINTO classification criteria. Control group consists of patients with other autoinflammatory diseases. A total of 1291 patients were classified into three groups according to their mutations: group 1: 447 patients with homozygous mutations; group 2: 429 patients with compound heterozygous mutations; and group 3: 415 patients with one heterozygous mutation. Similar diagnostic utility was found according to Livneh criteria between groups. But, proportion of patients fulfilling Tel-Hashomer and pediatric criteria was higher in groups 1 and 2. According to Eurofever/PRINTO criteria, 98.2% of patients with homozygous mutations, 94.2% of patients with compound heterozygous mutations and 80.2% of patients with heterozygous mutations were classified as FMF. In control group, 99.2% of them fulfilled the Livneh criteria, 66.9% met the pediatric criteria and 0.8% satisfied the Tel-Hashomer criteria, while none of control patients met the Eurofever/PRINTO classification criteria. Performances of three validated diagnostic criteria and new Eurofever/PRINTO classification criteria for FMF were similar and provide high utility in diagnosing/classifying patients with homozygous and compound heterozygous mutations. However, both Eurofever/PRINTO classification criteria and Tel-Hashomer criteria had significantly lower performance in heterozygous patients
Overlap of ILAR and Preliminary PRINTO Classification Criteria for Non-Systemic Juvenile Idiopathic Arthritis in an Established UK Cohort: Results from the Childhood Arthritis Prospective Study
No full textObjectives: To assess the degree of overlap between existing International League of Associations for Rheumatology (ILAR) and preliminary Pediatric Rheumatology International Trials Organization (PRINTO) classification criteria for JIA.Methods: Participants from the Childhood Arthritis Prospective Study, a multicentre UK JIA inception cohort, were classified using the PRINTO and ILAR classification criteria into distinct categories. Systemic JIA was excluded as several classification items were not collected in this cohort. Adaptations to PRINTO criteria were required to apply to a UK healthcare setting, including limiting the number of blood biomarker tests required. The overlap between categories under the two systems was determined and any differences in characteristics between groups described.Results: A total of 1,223 children and young people with a physician’s diagnosis of JIA were included. Using PRINTO criteria, the majority of children had “Other JIA” (69.5%). There was a high degree of overlap (91%) between the PRINTO enthesitis/spondylitis- and ILAR enthesitis-related JIA categories. The PRINTO RF-positive category was composed of 48% ILAR RF-positive polyarthritis and 52% undifferentiated JIA. The early-onset ANA-positive PRINTO category was largely composed of ILAR oligoarthritis (50%), RF-negative polyarthritis (24%) and undifferentiated JIA (23%). Few children were unclassified under PRINTO (n=3) and would previously have been classified as enthesitis-related JIA (n=1) and undifferentiated JIA (n=2) under ILAR. Conclusion: Under the preliminary PRINTO classification criteria for childhood arthritis, most children are not yet classified into a named category. These data can help support further delineation of the PRINTO criteria to ensure homogenous groups of children can be identified. <br/
Rancang Bangun Modul Production pada Aplikasi Printo Berbasis Mobile di PT Kotak Pratama Solusindo
No full textLaporan kerja magang ini berisi laporan pengembangan aplikasi Printo yang
berbasis mobile. Aplikasi mobile merupakan salah satu hasil dari perkembangan
teknologi di dunia dan banyak digunakan di seluruh dunia. Aplikasi mobile ketegori
bisnis merupakan aplikasi ketiga terbanyak yang digunakan di Indonesia. Aplikasi
Printo merupakan sebuah aplikasi yang digunakan untuk mencetak poster berisi
kata-kata motivasi atau gambar yang diunggah sendiri oleh pengguna. Aplikasi ini
dibangun dengan menggunakan framework Ionic 3 untuk tampilan aplikasi,
Angular 4 untuk menampilkan data ke pengguna, Typescript untuk mengatur proses
yang berjalan dalam aplikasi, dan API untuk proses pengambilan data dari database
perusahaan. Perancangan dan pembangungan aplikasi berhasil dilakukan sesuai
dengan kebutuhan yang ditentuka
The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis
No full textObjectives To develop data-driven criteria for clinically inactive disease on and off therapy for juvenile dermatomyositis (JDM)
Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis.
No full textOBJECTIVE: To identify preliminary core sets of outcome variables for disease activity and damage assessment in juvenile systemic lupus erythematosus (JSLE) and juvenile dermatomyositis (JDM).
METHODS: Two questionnaire surveys were mailed to 267 physicians from 46 different countries asking each member to select and rank the response variables used when assessing clinical response in patients with JSLE or JDM. Next, 40 paediatric rheumatologists from 34 countries met and, using the nominal group technique, selected the domains to be included in the disease activity and damage core sets for JSLE and JDM.
RESULTS: A total of 41 response variables for JSLE and 37 response variables for JDM were selected and ranked through the questionnaire surveys. In the consensus conference, domains selected for both JSLE and JDM activity or damage core sets included the physician and parent/patient subjective assessments and a global score tool. Domains specific for JSLE activity were the immunological tests and the kidney function parameters. Concerning JDM, functional ability and muscle strength assessments were indicated for both activity and damage core sets, whereas serum muscle enzymes were included only in the activity core set. A specific paediatric domain called 'growth and development' was introduced in the disease damage core set for both diseases and the evaluation of health-related quality of life was advised in order to capture the influence of the disease on the patient lifestyle.
CONCLUSIONS: We developed preliminary core sets of measures for disease activity and damage assessment in JSLE and JDM. The prospective validation of the core sets is in progress
- …
